Literature DB >> 27601965

The Role of Estrogen Modulators in Male Hypogonadism and Infertility.

Amarnath Rambhatla1, Jesse N Mills1, Jacob Rajfer1.   

Abstract

Estradiol, normally considered a female hormone, appears to play a significant role in men in a variety of physiologic functions, such as bone metabolism, cardiovascular health, and testicular function. As such, estradiol has been targeted by male reproductive and sexual medicine specialists to help treat conditions such as infertility and hypogonadism. The compounds that modulate estradiol levels in these clinical conditions are referred to as selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs). In a certain subset of infertile men, particularly those with hypogonadism, or those who have a low serum testosterone to estradiol ratio, there is some evidence suggesting that SERMs and AIs can reverse the low serum testosterone levels or the testosterone to estradiol imbalance and occasionally improve any associated infertile or subfertile state. This review focuses on the role these SERMs and AIs play in the aforementioned reproductive conditions.

Entities:  

Keywords:  Aromatase inhibitor; Hypogonadism; Male infertility; Selective estrogen receptor modulator

Year:  2016        PMID: 27601965      PMCID: PMC5010627          DOI: 10.3909/riu0711

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  51 in total

1.  Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

Authors:  Christina Wang; Glenn Cunningham; Adrian Dobs; Ali Iranmanesh; Alvin M Matsumoto; Peter J Snyder; Thomas Weber; Nancy Berman; Laura Hull; Ronald S Swerdloff
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

2.  Estrogen receptor gene polymorphism, but not estradiol levels, is related to bone density in healthy adolescent boys: a cross-sectional and longitudinal study.

Authors:  M Lorentzon; R Lorentzon; T Bäckström; P Nordström
Journal:  J Clin Endocrinol Metab       Date:  1999-12       Impact factor: 5.958

3.  Gonadal steroids and body composition, strength, and sexual function in men.

Authors:  Joel S Finkelstein; Hang Lee; Sherri-Ann M Burnett-Bowie; J Carl Pallais; Elaine W Yu; Lawrence F Borges; Brent F Jones; Christopher V Barry; Kendra E Wulczyn; Bijoy J Thomas; Benjamin Z Leder
Journal:  N Engl J Med       Date:  2013-09-12       Impact factor: 91.245

4.  The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia.

Authors:  Elena Tsourdi; Anargyros Kourtis; Dimitrios Farmakiotis; Ilias Katsikis; Marios Salmas; Dimitrios Panidis
Journal:  Fertil Steril       Date:  2008-08-09       Impact factor: 7.329

5.  Treatment of idiopathic oligozoospermia with tamoxifen--a randomized controlled study.

Authors:  W Krause; H Holland-Moritz; P Schramm
Journal:  Int J Androl       Date:  1992-02

6.  Combination clomiphene citrate and antioxidant therapy for idiopathic male infertility: a randomized controlled trial.

Authors:  Hussein Ghanem; Osama Shaeer; Amgad El-Segini
Journal:  Fertil Steril       Date:  2009-03-06       Impact factor: 7.329

7.  Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial.

Authors:  Sherri-Ann M Burnett-Bowie; Kristen C Roupenian; Melissa E Dere; Hang Lee; Benjamin Z Leder
Journal:  Clin Endocrinol (Oxf)       Date:  2009-01       Impact factor: 3.478

8.  Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels.

Authors:  Sherri-Ann M Burnett-Bowie; Elizabeth A McKay; Hang Lee; Benjamin Z Leder
Journal:  J Clin Endocrinol Metab       Date:  2009-10-09       Impact factor: 5.958

9.  Clomiphene citrate: pharmacologic treatment of hypofertile male.

Authors:  D F Paulson; C B Hammond; R de Vere White; R H Wiebe
Journal:  Urology       Date:  1977-04       Impact factor: 2.649

10.  Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit?

Authors:  A T Guay; J Jacobson; J B Perez; M B Hodge; E Velasquez
Journal:  Int J Impot Res       Date:  2003-06       Impact factor: 2.896

View more
  6 in total

1.  Comparison of the effect of combined therapy of HCG ampule and letrozole tablet with each method separately on the spermogram parameters in the obese men with idiopathic infertility: a clinical trial.

Authors:  Yadollah Ahmadi-Asrbadr; Mahdi Hemmati-Ghavshough; Navid Khanzadeh; Fereshteh Ansari; Mohsen Mohammad-Rahimi
Journal:  Am J Clin Exp Urol       Date:  2022-08-15

Review 2.  The role of the androgen receptor in the pathogenesis of obesity and its utility as a target for obesity treatments.

Authors:  Varun S Venkatesh; Mathis Grossmann; Jeffrey D Zajac; Rachel A Davey
Journal:  Obes Rev       Date:  2022-01-27       Impact factor: 10.867

Review 3.  Are sex discordant outcomes in COVID-19 related to sex hormones?

Authors:  Jonathan D Strope; Cindy H Chau; William D Figg
Journal:  Semin Oncol       Date:  2020-06-17       Impact factor: 4.929

4.  Prolonged use of letrozole causes morphological changes on gonads in Galea spixii.

Authors:  Maria Angelica Machado Arroyo; Paulo Ramos da Silva Santos; Moacir Franco de Oliveira; Antônio Chaves de Assis
Journal:  Anim Reprod       Date:  2021-07-12       Impact factor: 1.807

5.  Treatment of Estrogen Levels in the Management of Hypogonadism: An Anonymous Survey of ISSM Members.

Authors:  Mohit Butaney; Nannan Thirumavalavan; Adithya Balasubramanian; J Abram McBride; Jabez Gondokusumo; Alexander W Pastuszak; Larry I Lipshultz
Journal:  Urology       Date:  2020-02-08       Impact factor: 2.649

6.  Baseline Gonadotropin Levels and Testosterone Response in Hypogonadal Men Treated With Clomiphene Citrate.

Authors:  Sorena Keihani; Lindsey N Wright; Nathan J Alder; Jinfeng Jiang; Philip J Cheng; Gregory J Stoddard; Alexander W Pastuszak; Christopher M Deibert; James M Hotaling
Journal:  Urology       Date:  2020-04-28       Impact factor: 2.649

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.